NIH Ends Clinical Trial of Eli Lily's Coronavirus Antibody Therapy Candidate

Eric Volkman, The Motley Fool
·2-min read
NIH Ends Clinical Trial of Eli Lily's Coronavirus Antibody Therapy Candidate
NIH Ends Clinical Trial of Eli Lily's Coronavirus Antibody Therapy Candidate

LY-CoV555, which was being tested in combination with Gilead Sciences' remdesivir, showed no evidence of benefiting hospitalized COVID-19 patients.